|
1
|
Arteaga CL: Epidermal growth factor
receptor dependence in human tumors: More than just expression?
Oncologist. 4:(Supp 7). S31–S39. 2002. View Article : Google Scholar
|
|
2
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gazdar AF, Shigematsu H, Herz J and Minna
JD: Mutations and addiction to EGFR: The Achilles ‘heal’ of lung
cancers? Trends Mol Med. 10:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsieh RK, Lim KH, Kuo HT, Tzen CY and
Huang MJ: Female sex and bronchioloalveolar pathologic subtype
predict EGFR mutations in non-small cell lung cancer. Chest.
128:317–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shih JY, Gow CH, Yu CJ, et al: Epidermal
growth factor receptor mutations in needle biopsy/aspiration
samples predict response to gefitinib therapy and survival of
patients with advanced nonsmall cell lung cancer. Int J Cancer.
118:963–969. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh
NT, Jackson S, Jackson C and Van Waes C: Effects of pharmacologic
antagonists of epidermal growth factor receptor, PI3K and MEK
signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF
expression in human head and neck squamous cell carcinoma lines.
Int J Cancer. 99:538–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldman CK, Kim J, Wong WL, King V, Brock
T and Gillespie GY: Epidermal growth factor stimulates vascular
endothelial growth factor production by human malignant glioma
cells: A model of glioblastoma multiforme pathophysiology. Mol Biol
Cell. 4:121–133. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ravindranath N, Wion D, Brachet P and
Djakiew D: Epidermal growth factor modulates the expression of
vascular endothelial growth factor in the human prostate. J Androl.
22:432–443. 2001.PubMed/NCBI
|
|
10
|
Hirata A, Ogawa S, Kometani T, Kuwano T,
Naito S, Kuwano M and Ono M: ZD1839 (Iressa) induces antiangiogenic
effects through inhibition of epidermal growth factor receptor
tyrosine kinase. Cancer Res. 62:2554–2560. 2002.PubMed/NCBI
|
|
11
|
Ciardiello F, Caputo R, Bianco R, Damiano
V, Fontanini G, Cuccato S, De Placido S, Bianco AR and Tortora G:
Inhibition of growth factor production and angiogenesis in human
cancer cells by Z (Iressa), a selective epidermal growth factor
receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:1459–1465.
2001.PubMed/NCBI
|
|
12
|
Ferrara N: Vascular endothelial growth
factor: Basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimanuki Y, Takahashi K, Cui R, Hori S,
Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular
endothelial growth factor in the prediction of angiogenesis and
prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maeshima Y, Sudhakar A, Lively JC, Ueki K,
Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R:
Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cote ML, Haddad R, Edwards DJ, Atikukke G,
Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG and Ethier
SP: Frequency and type of epidermal growth factor receptor
mutations in African Americans with non-small cell lung cancer. J
Thorac Oncol. 6:627–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia SF, Guan H, Duan X and Kleinerman ES:
VEGF165 is necessary to the metastatic potential of Fas (−)
osteosarcoma cells but will not rescue the Fas (+) cells. J Exp
Ther Oncol. 7:89–97. 2008.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reinmuth N, Jauch A, Xu EC, Muley T,
Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth
FJ, et al: Correlation of EGFR mutations with chromosomal
alterations and expression of EGFR, ErbB3 and VEGF in tumor samples
of lung adenocarcinoma patients. Lung cancer. 62:193–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosell R, Ichinose Y, Taron M, Sarries C,
Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B,
et al: Mutations in the tyrosine kinase domain of the EGFR gene
associated with gefitinib response in non-small-cell lung cancer.
Lung Cancer. 50:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bruns CJ, Solorzano CC, Harbison MT, Ozawa
S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R
and Fidler IJ: Blockade of the epidermal growth factor receptor
signaling by a novel tyrosine kinase inhibitor leads to apoptosis
of endothelial cells and therapy of human pancreatic carcinoma.
Cancer Res. 60:2926–2935. 2000.PubMed/NCBI
|
|
26
|
Sun L, Ma JT, Zhang SL, Zou HW and Han CB:
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors
combined with bevacizumab versus chemotherapy or tyrosine kinase
inhibitors alone in the treatment of non-small cell lung cancer: A
systematic review and meta-analysis. Med Oncol. 32:4732015.
View Article : Google Scholar : PubMed/NCBI
|
